Dataset opportunity
Corcym — 医疗影像数据集机会
Corcym 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
63.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2024 年为 17.5 亿美元，复合年增长率为 30%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Corcym 持有专有的医疗影像数据集，其中包含来自临床试验的影像模态，并辅以相应的 `medical_records` 和 `business_records`。这个经过精心策划的高质量集合，旨在用于开发和验证诊断人工智能算法，在 Corcym 专长的领域——心血管领域具有显著潜力。
商业价值根植于快速扩张的医疗影像人工智能市场，该市场在 2024 年的估值为17.5 亿美元，预计将以惊人的30% 的复合年增长率增长。[6] 尽管存在固有的访问复杂性，例如严格的 GDPR/HIPAA 合规性和数据所有权共享，但该数据具有监管级别的质量和稀有性，对于寻求抓住这一高增长市场份额的人工智能开发者来说，它是一项极其宝贵的资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床数据涉及敏感的患者健康信息 (PHI)，需要严格的 GDPR/HIPAA 合规性；临床试验的数据所有权可能与医疗保健提供者或研究机构共享；高度管制的医疗器械行业需要特定的数据治理才能进行二次使用 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据表明 Corcym 拥有专有的临床证据数据集，包括医学影像，重点关注结构性心脏疾病及相关医疗器械。这类专业数据受到寻求训练和验证先进心脏应用算法的诊断人工智能开发者的追捧。在全球医疗影像人工智能市场预计于 2024 年达到 17.5 亿美元并以每年 30% 的速度增长的情况下，访问如此稀有的数据集提供了显著的竞争优势。它代表了一个独特的机会，可以构建由成熟的医疗器械创新者提供的数据支持的下一代诊断工具。
See dimension details ↓- Dataset Specificity78
主导的“医疗记录”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 条证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家对高质量医疗影像数据的需求异常高，这得益于医疗影像人工智能市场的激进扩张，复合年增长率为 30%。[6]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 条命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit75
✓ 良好目标 — Corcym 是一个良好目标，因为它制造和销售手术心脏瓣膜，作为其核心业务的副产品，生成有价值的临床和设备性能数据，并且似乎不将这些数据或衍生智能作为产品出售。问题：公司约有 850 名员工，比典型中小企业规模大，这可能会影响决策速度；公司是从剥离业务中成立的，并得到私募股权支持，这可能意味着对数据资产采取更结构化、不那么“休眠”的方法，尽管 t
- Deep Qualification80
✓ 通过 — Corcym 是一家医疗器械制造商，其商业模式基于销售心脏手术产品；它不销售数据。它持有宝贵的临床和影像数据，作为研发和上市后研究的副产品，但所有权复杂且可能与研究伙伴共享，使得二次使用的许可权不明确。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该公司持有来自其心脏瓣膜设备开发和验证的临床证据，可能包括医学影像，这是训练诊断人工智能模型处理特定心脏病的宝贵资产。
Industrial data
这些证据指向该公司精密工程医疗设备的性能和工程数据，可用于开发设备结果的预测模型。
business_records
公司文件证实，该数据来自一家专注于结构性心脏领域的全球医疗器械公司，确保了数据集的相关性和来源。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Corcym Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.75 billion in 2024, CAGR 30% (source: Roots Analysis). Investment score 63.1/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Skarvshipping — 移动遥测数据集机会
View opportunity →工业Donaldsontimbersystems — 开发者数据平台机会
View opportunity →工业Aquacycl — 维护日志数据集机会
View opportunity →